Table 5 Relationship between BRAF mutational status detected by CAST-PCR and different clinicopathological parameters in 26 studied melanoma cases using the chi-square test

Gender

 Male

2 (33.3%)

9 (45%)

P(FE) = 0.674 NS

 Female

4 (67.7%)

11 (55%)

Anatomic site

 Acral

3 (50%)

13 (65%)

P_(FE) = 0.644 NS

 Non acral

3 (50%)

7 (35%)

Histologic type

 SSM

0

2 (10%)

p_(MC) = 0.710 NS

 LMM

1 (16.7%)

1 (5%)

 NM

2 (33.3%)

4 (20%)

 ALM

3 (50%)

9 (45%)

 Melanoma, NOS

0

4 (20%)

Tumour size

 T1

0

1 (5%)

P_(MC) = 0.445 NS

 T2

1 (16.7%)

0

 T3

2 (33.3%)

8 (40%)

 T4

3 (50%)

11 (55%)

Ulceration

 Detected

2 (33.3%)

11 (55%)

P_(FE) = 0.568 NS

 Not detected

4 (66.7%)

9 (45%)

In situ component

 Detected

2

12

P_(FE) = 0.365 NS

 Not detected

4

8

Lymphovascular invasion

 Detected

2 (33.3%)

7 (35%)

P_(FE) = 1.00 NS

 Not detected

4 (66.7%)

13 (65%)

Neurotropism

 Detected

0

2 (10%)

P_(FE) = 1.00 NS

 Not detected

6

18 (90%)

Tumour-infiltrating lymphocytes

 No TILs

1 (16.7%)

2 (10%)

p_(MC) = 0.335 NS

 TILs identified, nonbrisk

4 (66.7%)

18 (90%)

 TILs identified, brisk

1 (16.7%)

0

Regression

 Present

2 (33.3%)

4 (20%)

P_(FE) = 0.596

 Absent

4 (66.7%)

16 (80%)

Nodal status (assessed only in six cases)

 Involved

2 (100%)

3 (75%)

p_(FE) = 0.667 NS

 Not involved

0

1 (25%)